Title: Lessons from the EP lab
1Lessons from the EP lab
- Reversal of Idiopathic Cardiomyopathies
Steven Compton, MD, FACC, FACP Alaska Heart
Institute
2Idiopathic Cardiomyopathy
- A disease of unknown etiology that principally
affects the myocardium
Gilbert, EM and Bristow, MR, in Schlant and
Alexander The Heart 8th ed., 1994.
3Idiopathic Cardiomyopathy
- Diagnosis is established by the presence of LV
dilatation and systolic dysfunction in the
absence of congenital, coronary, valvular,
hypertensive, or pericardial heart disease.
Gilbert, EM and Bristow, MR, in Schlant and
Alexander The Heart 8th ed., 1994.
4Idiopathic Cardiomyopathy
- Distinct from secondary myocardial diseases that
occur with a specific systemic disorder that may
be metabolic, collagen-vascular, infiltrative,
neuromuscular, inflammatory, toxic, genetic, or
neoplastic in origin.
Gilbert, EM and Bristow, MR, in Schlant and
Alexander The Heart 8th ed., 1994.
5Idiopathic Cardiomyopathy
- Since IDC is defined clinically, it is likely
that several specific etiologies are responsible
for this condition.
Gilbert, EM and Bristow, MR, in Schlant and
Alexander The Heart 8th ed., 1994.
6Idiopathic Cardiomyopathyno longer
- Tachycardia induced cardiomyopathy
- Atrial fibrillation-induced cardiomyopathy
- Ventricular ectopy-induced cardiomyopathy
- Dyssynchronous cardiomyopathy
7Tachycardia-induced cardiomyopathy
- Caused by any sustained, fast rhythm
- Atrial rhythms
- Afib, Aflut, AT
- AVRT, esp. PJRT
- AVNRT
- VT
- Idiopathic VTs
- Ischemic VTs
- BBRT VTs
- Sustained rapid pacing
8Tachycardia-induced cardiomyopathy
- Clinical clues dating back to 1910
- Reversal with ablation demonstrated late
80s/early 90s - Review article 1997 (Shinbane et al, JACC)
- Heart rate and rhythm control should be
rigorously and rapidly pursued if definite signs
of a cardiomyopathic process have developed.
9TICM Findings
- Ventricular cardiomyopathy
- Gross changes
- Dilated ventricle
- Reduced LV contractility
- Elevated LV end-diastolic pressure
- Mitral regurgitation (2? to annular dilatation)
- Abnormal LV torsion
- LV diastolic dysfunction
10TICM Microscopic changes
- Myocyte lengthening, hyperplasia
- Disruption of basement membranesarcolemmal
junction - Reduced myocardial capillaries and reduced blood
flow - Impaired coronary reserve
- Myocardial fibrosis
11Molecular changes
- ß-receptor expression reduced, transduction
reduced - Reduced adenylate cyclase activity
- Abnormal excitation-contraction coupling
- T-tubule depletion
- Apoptosis
12Atrial cardiomyopathy
- Atrial dilatation
- Contractile dysfunction
- Abnormal calcium channel function
- Na/Ca2-exchanger upregulation
- Intracellular Ca2 loading
13Clinical observations
- LV dysfunction correlates with
- Tachycardia rate
- Tachycardia duration
- Ventricular vs. atrial mechanism
- Reports of reversal with ablation relate to
grossly observed LV contractility. Reversal of
LV dysfunction may not be complete.
14Afib induced CM
- 36 y/o WM with lone afib
- Normal echo and thyroid studies. Holter mean
rate 74 bpm. - 3 years later
- Exertional intolerance. LVEF 30, mild MR.
Fails dofetilide, declines amiodarone. -
15Atrial fibrillation ablation
16Post ablation
- 4 weeks post ablation
- Bags fall moose, 3 mile haulout
- Back to full activity
- 6 months post ablation
- Persistent NSR
- Normal LV function
- 2 years post ablation
- NSR, Normal LV
17Catheter Ablation for Atrial Fibrillation in
Congestive Heart Failure
Li-Fern Hsu, M.B., B.S., Pierre Jais, M.D.,
Prashanthan Sanders, M.B., B.S., Ph.D., Stephane
Garrigue, M.D., Ph.D., Meleze Hocini, M.D.,
Frederic Sacher, M.D., Yoshihide Takahashi, M.D.,
Martin Rotter, M.D., Jean-Luc Pasquie, M.D.,
Ph.D., Christophe Scavee, M.D., Pierre Bordachar,
M.D., Jacques Clementy, M.D. and Michel
Haissaguerre, M.D.
N Engl J Med Volume 351232373-2383 December 2,
2004
18Improvement in Left Ventricular (LV) Function and
Dimensions after Ablation in Patients with
Congestive Heart Failure
19Hsu, L. et al. N Engl J Med 20043512373-2383
20AF Cardiomyopathy
- Restoration of sinus rhythm by ablation of AF in
CHF can significantly improve cardiac function,
symptoms, exercise capacity, and quality of life. - Cardiomyopathy can improve or resolve despite
prior rate control. - Mechanisms of improvement?
- Regularization of ventricular activation?
- Restoration of atrial transport function?
21AF Cardiomyopathy
- AVN ablation/BIV vs PVI trial rate controlled
patients
Khan et al, N Engl J Med 20083591778-85.
22PVC-induced Cardiomyopathy
LVEF 40 NYHA III
LVEF 55 NYHA I
23PVC-induced Cardiomyopathy
- Resolves with treatment
- First description 2000 (Chugh et al JCVEP)
- Independent of PVC source
- RVOT
- LV septum
- Ischemic scar
- Mechanism?
24Dyssynchronous Cardiomyopathy
25Case Report
- 58 y/o IDC EF 10, Class IV CHF
- Bimonthly hospitalizations for CHF
- Maximally tolerated medical therapy
26Carl Kron
Marked First Degree AV block LBBB
27Class IV
28Epicardial LV Lead
29Class IV
30Class II
Class IV
31LVEF 10 NYHA IV
LVEF 50 NYHA I
2002
32Super-responders
- Decrease in New York Heart Association functional
class 1 - 2-fold or more LVEF increase or final LVEF gt45,
- and
- Decrease in LV end-systolic volume gt15
Antonio et al, Europace 2009 11(3)343-349
33Super-responders
- Definitions vary but involve restoration of
near-normal or normal LV function. - 7-22 of CRT patients super-respond
- Predictors absence of scar, shorter duration of
dysfunction, less LV dilatation. - Implies existence of dyssynchrony as sole cause
of cardiomyopathy in some patients.
Antonio et al, Europace 2009 11(3)343-349 Ypenbur
g et al, JACC 2009 53(6)483-490
34Dyssynchronous Cardiomyopathy
35Idiopathic Cardiomyopathyno longer
- Tachycardia induced cardiomyopathy
- Atrial fibrillation-induced cardiomyopathy
- Ventricular ectopy-induced cardiomyopathy
- Dyssynchronous cardiomyopathy